Renovis Announces Management Changes
02 Ottobre 2007 - 1:00AM
PR Newswire (US)
CEO Corey Goodman Steps Down; John Walker, Board Chair, Named
Executive Chairman SOUTH SAN FRANCISCO, Calif., Oct. 1
/PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), a
biopharmaceutical company focused on the discovery and development
of drugs for major medical needs in the areas of neurological and
inflammatory diseases, today announced that Corey Goodman, Ph.D.,
will step down today as President and Chief Executive Officer to
pursue another opportunity. Dr. Goodman will continue to serve as a
Renovis Board member until such time as the Company merges with
Evotec AG (XETRA:EVT.DE), the Hamburg, Germany-based CNS drug
discovery and development company, with which Renovis announced the
signing of a definitive merger agreement on September 19, 2007.
Following the merger, it is anticipated that Dr. Goodman will serve
on Evotec's Supervisory Board as well as on its Scientific Advisory
Board. Renovis Chairman of the Board, John Walker, will assume the
position of Executive Chairman effective October 2, 2007, with
responsibility for working with the executive management team. Dr.
Goodman commented, "Since helping co-found Renovis in 2000 and
becoming its CEO in 2001, it has been my privilege to lead our
uniquely talented team of scientists and biotech professionals.
This group has distinguished itself in its entrepreneurial approach
to drug discovery in the areas of neurological disease, pain, and
inflammation. I am particularly proud of our portfolio of drug
candidates for pain targeting members of the TRP and purinergic
families of ligand-gated ion channels. Our team's work led to our
collaboration on VR1 antagonists with Pfizer, our nerve growth and
angiogenesis collaboration with Genentech, as well as our other
programs and the opportunities we have in our proposed merger with
Evotec." "I believe that the proposed merger with Evotec,
unanimously endorsed by our Board of Directors, represents an
important opportunity to bring the advances and accomplishments of
the Renovis scientific team to fruition. Our strengths in drug
discovery and preclinical development are synergistic to the
capabilities already resident in Evotec, including the strength of
their clinical team. I am delighted to have the opportunity to help
guide and advise the progress of the combined companies in my new
roles as board member and scientific advisor. At Renovis, we have
always been committed to translating great science into
groundbreaking medicines that improve the lives of patients; as
part of Evotec, I believe we can transform that vision into
reality." According to John Walker, just named Executive Chairman,
"As a founder of Renovis and as its CEO, Corey Goodman
distinguished himself once more as a scientific leader as well as a
successful biotech entrepreneur. A skilled communicator, Corey
guided the Company's initial public offering and effectively
broadened support for Renovis on Wall Street, while at the same
time, applying his keen scientific insight and dogged persistence
in the discovery of important new small molecules for pain and
inflammatory indications. His enthusiasm inspired all of us on the
Board as well as the professionals with whom he worked throughout
the organization. Clearly, he has devoted himself to applying broad
scientific and business expertise to the Company's goal of becoming
a leading biopharmaceutical company focused on discovering,
developing, and commercializing drugs to treat neurological and
inflammatory diseases. He will be sorely missed. We wish him well
in his next endeavor." "In my new role as Executive Chairman, I
will work with the members of the Renovis executive team to move
our programs forward, to communicate with shareholders, and to take
the necessary steps to complete the proposed transaction with
Evotec. Corey and I will continue to work together on the Renovis
Board of Directors, and following the merger, on the Evotec
Supervisory Board," continued Walker. Dr. Corey Goodman co-founded
Renovis in 2000 and joined Renovis as CEO in September of 2001.
John Walker joined the Company's Board of Directors in January of
2003 and in November of 2005 became its Chairman. Walker is also
CEO and Chairman of Novacea, Inc. a biopharmaceutical firm focused
on oncology, located nearby in South San Francisco. About Renovis
Renovis is a biopharmaceutical company focused on the discovery and
development of drugs for major medical needs in the areas of
neurological and inflammatory diseases. The Company's proprietary
research programs focus on the purinergic receptors, P2X3 and P2X7,
for the potential treatment of pain and inflammatory diseases. In
addition, Renovis has worldwide collaboration and license
agreements with Pfizer to research, develop and commercialize small
molecule vanilloid receptor (VR1) antagonists and an agreement with
Genentech, Inc. in the areas of nerve growth and anti-angiogenesis.
For additional information about the Company, please visit
http://www.renovis.com/. Additional information about the
transaction Renovis filed a Current Report on Form 8-K with the
Securities and Exchange Commission on September 24, 2007 that
includes as an exhibit the Agreement and Plan of Merger between
Evotec and Renovis. Evotec intends to file a Registration Statement
on Form F-4 with the Securities and Exchange Commission in
connection with the proposed merger. Evotec and Renovis expect to
mail a joint proxy statement/prospectus, which will form part of
the Registration Statement on Form F-4, to shareholders of Renovis
in connection with the proposed merger. This document will contain
important information about the merger and should be read before
any decision is made with respect to the merger. Investors and
stockholders will be able to obtain free copies of this document
and any other documents filed or furnished by Evotec or Renovis
through the website maintained by the Securities and Exchange
Commission at http://www.sec.gov/. Free copies of these documents
may also be obtained from Evotec, by directing a request to
Evotec's Investor Relations department at Schnackenburgallee 114,
22525 Hamburg, Germany, or from Renovis, by directing a request to
Renovis' Investor Relations department at Two Corporate Drive,
South San Francisco, California 94080. In addition to the documents
referenced above, Renovis files or furnishes annual, quarterly and
current reports, proxy statements and other information with the
Securities and Exchange Commission. You may read and copy any
reports, statements or other information filed or furnished by
Renovis at the SEC's Public Reference Room at Station Place, 100 F
Street, N.E., Washington, D.C. 20549. You can request copies of
these documents by writing to the SEC and paying a fee for the
copying cost. Please call the SEC at 1-800-SEC-0330 for more
information about the operation of the Public Reference Room.
Renovis's SEC filings are also available to the public at the SEC's
web site at http://www.sec.gov/, or at their web site at
http://www.renovis.com/. Safe Harbor Statement This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release
regarding our strategy, future operations, future financial
results, preclinical and clinical development activities,
anticipated preclinical and clinical development progress, the
plans and objectives of management, the benefits expected from the
contemplated transaction between Evotec and Renovis and the timing
of the completion of the transaction are forward-looking statements
and are based on current expectations and estimates. We may not
actually achieve these plans, intentions or expectations and
investors should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements we make. Various important factors that
could cause actual results or events to differ materially from the
forward-looking statements include, but are not limited to, the
risk that the conditions relating to the required regulatory
clearance might not be satisfied in a timely manner or at all,
risks relating to the integration of the technologies and
businesses of Evotec and Renovis, unanticipated expenditures,
changing relationships with customers, suppliers and strategic
partners, conditions of the economy and other factors described in
greater detail in reports filed with Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q, which was
filed on August 8, 2007, our Annual Report on Form 10-K, which was
filed on March 15, 2007, and the Registration Statement on Form F-4
that will be filed by Evotec. Renovis is providing this information
as of the date of this press release and does not undertake any
obligation to update any forward-looking statements as a result of
new information, future events or otherwise. DATASOURCE: Renovis,
Inc. CONTACT: Shari Annes of Renovis, Inc., +1-650-888-0902, Web
site: http://www.renovis.com/
Copyright
Grafico Azioni Renovis (MM) (NASDAQ:RNVS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Renovis (MM) (NASDAQ:RNVS)
Storico
Da Giu 2023 a Giu 2024